Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™

NOTE: Enrollment open only to military personnel Inclusion Criteria: * Signed informed consent and HIPAA authorization. * Refractive error, based on the iDesign displayed refraction must be myopia with or without astigmatism with sphere up to -8.00 D, and cylinder between 0.00 D and -4.00 D with maximum SE of -10.00 D. * Anticipated residual stromal bed thickness of at least 250 microns as calculated by the iDesign system. * Distance Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better * BSCVA ≥2 lines (≥10 letters) better than distance Uncorrected Visual Acuity (UCVA). * Less than or equal to 0.75 D difference between cycloplegic and manifest refraction sphere. * Stable refractive error as defined by a change of ≤1.00 D in MRSE over at least a 12 month time period. * Any subject eye with a history of contact lens wear within the last 4 weeks must demonstrate refractive stability * Agreement between manifest refraction (adjusted for optical infinity) and iDesign System refraction chosen for treatment. * Willing and capable of complying with follow-up examinations for the duration of the study. Exclusion Criteria: * Women who are pregnant, breast-feeding, or intend to become pregnant, or not using an adequate method of birth control. * Concurrent use of systemic (including inhaled) medications that may impair healing. * History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis. * Subjects with a cardiac pacemaker, implanted defibrillator or other implanted electronic device. * History of prior intraocular or corneal surgery, active ophthalmic disease or abnormality, retinal detachment/repair, clinically significant lens opacity, clinical evidence of trauma, corneal opacity within the central 9 mm and visible on topography, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma. * Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal topography * Known sensitivity or inappropriate responsiveness to any of the medications used in this study. * If either eye does not meet all inclusion criteria * Desire to have monovision. * Participation in any other clinical study, with the exception of the fellow eye in this study.